WANG LABORATORIES INC
10-Q/A, 1999-04-06
PREPACKAGED SOFTWARE
Previous: VISHAY INTERTECHNOLOGY INC, PRE 14A, 1999-04-06
Next: WANG LABORATORIES INC, 8-K/A, 1999-04-06



<PAGE>   1

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-Q/A
                          AMENDMENT NO. 1 TO FORM 10-Q

(Mark One)

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
      EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 1998

                                       OR

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
      EXCHANGE ACT OF 1934

For the transition period from __________ to __________

                          Commission file number 1-5677

                             WANG LABORATORIES, INC.
                             -----------------------
             (Exact name of registrant as specified in its charter)

             DELAWARE                                   04-2192707
             --------                                   ----------
  (State or other jurisdiction of        (I.R.S. Employer Identification Number)
  incorporation or organization)

              290 CONCORD ROAD
          BILLERICA, MASSACHUSETTS                           01821-4130
  ----------------------------------------                   ----------
  (Address of principal executive offices)                   (Zip Code)

                                 (978) 625-5000
                                 --------------
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
                                 --------------
              (Former name, former address and former fiscal year,
                          if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during
the preceding twelve months, and (2) has been subject to such filing
requirements for the past 90 days. 
Yes [X]  No [ ]

Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court. Yes [X]  No [ ]

Indicate the number of shares outstanding of each of the registrant's classes of
common stock, as of the latest practical date (March 31, 1998):

Common stock, par value $0.01 per share                    45,948,952 shares


                                        1
<PAGE>   2

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                                      INDEX

PART I. FINANCIAL INFORMATION                                           PAGE NO.

        ITEM 1. Consolidated Financial Statements (Unaudited)

                 Consolidated Balance Sheets -
                 March 31, 1998 (restated)  and June 30, 1997               3

                 Consolidated Statements of Operations -
                 Three and nine months ended March 31, 1998 and 1997        4

                 Consolidated Statements of Cash Flows -
                 Nine months ended March 31, 1998 and 1997                  5

                 Notes to Consolidated Financial Statements -
                 March 31, 1998                                             6

        ITEM 2.  Management's Discussion and Analysis of Financial
                 Condition and Results of Operations                       12

This Amendment to the Quarterly Report on Form 10-Q of Wang Laboratories, Inc.
("Wang" or the "Company") for the three and nine months ended March 31, 1998
gives effect to certain changes in Item 1 - Consolidated Financial Statements
(Unaudited) and Item 2 Management's Discussion and Analysis of Financial
Condition and Results of Operations.

This Amendment, which is the result of informal discussions with the staff of
the Securities and Exchange Commission which concluded in March 1999, reflects
an adjustment to the valuation of 8.75 million shares (of which 1.5 million are
to be delivered upon shareholder approval) and 5.0 million Stock Appreciation
Rights ("SARs") issued to Olivetti as part consideration for the acquisition of
Olsy. The adjustment results from the application of a 20% discount to a revised
calculation of market value compared to a previously applied discount of 35%.
The adjustment had the effect of increasing paid-in-capital by $41.0 million
with a corresponding increase in intangible assets.

Additionally, disclosures regarding EBITDA and the likelihood of future asset
impairments, have been expanded in Management's Discussion and Analysis of
Financial Condition and Results of Operations.

PART II. OTHER INFORMATION

         Item 6.  Exhibits and Reports on Form 8-K                       

                  The following document is included as part of this Quarterly
                  Report on Form 10-Q/A, Amendment No. 1 to Form 10-Q.

                  Exhibit 27.1 -- Financial Data Schedule (restated)

SIGNATURE                                                                  22


                                       2
<PAGE>   3

                         PART I - FINANCIAL INFORMATION

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                    (UNAUDITED)
                                                                                     MARCH 31,    JUNE 30,
                                                                                       1998         1997
                                                                                     ----------   --------
                                                                                     (RESTATED)
                                                                                     (DOLLARS IN MILLIONS)
<S>                                                                                  <C>          <C>     
ASSETS

CURRENT ASSETS
  Cash and equivalents                                                               $  238.7     $  242.2
  Accounts receivable, net of allowance for doubtful accounts 
    of $19.8 at March 31, 1998 and $17.9 million at June 30, 1997                       790.8        244.3
  Inventories:
   Finished products                                                                      8.2          5.6
   Raw materials and work-in-process                                                    134.5          7.8
   Service parts and supplies                                                            46.0          1.1
                                                                                     --------     --------
    Total inventories                                                                   188.7         14.5
  Other current assets                                                                  200.9         53.6
                                                                                     --------     --------
       Total current assets                                                           1,419.1        554.6

Depreciable assets, net of accumulated depreciation of $161.7 
  million at March 31, 1998 and $131.7 million at June 30, 1997                         292.1        123.0
Intangible assets, net of accumulated amortization of $83.4 million
  at March 31, 1998 and $64.2 million at June 30, 1997                                  450.6        311.6
Other                                                                                   117.8         45.6
                                                                                     --------     --------

       Total assets                                                                  $2,279.6     $1,034.8
                                                                                     ========     ========

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
   Borrowings due within one year                                                    $  120.3     $   63.3
   Accounts payable                                                                     381.5         64.4
   Accrued expenses                                                                     242.1        121.3
   Other current liabilities                                                            372.2        110.0
   Deferred service revenue                                                             156.1         69.5
                                                                                     --------     --------
       Total current liabilities                                                      1,272.2        428.5
                                                                                     --------     --------

Long-term liabilities                                                                   291.3         98.0
                                                                                     --------     --------

Commitments and contingencies

Minority interest                                                                         6.7            --

Series A Preferred Stock                                                                 86.0         85.5
                                                                                     --------     --------

STOCKHOLDERS' EQUITY
  Series B Preferred Stock, $0.01 par value, 143,750 shares
    authorized and outstanding, liquidation preference of $143.8 million                138.3        138.3
  Common stock, $0.01 par value, 100,000,000 shares authorized; outstanding
    shares: 45,948,952 at March 31, 1998 and 38,008,004 at June 30, 1997                  0.5          0.4
  Capital in excess of par value                                                        525.0        291.4
  Cumulative translation adjustment                                                      (8.6)        (3.7)
  Retained earnings (deficit)                                                           (31.8)        (3.6)
                                                                                     --------     --------
       Total stockholders' equity                                                       623.4        422.8
                                                                                     --------     --------

   Total liabilities and stockholders' equity                                        $2,279.6     $1,034.8
                                                                                     ========     ========

               See notes to the consolidated financial statements.
</TABLE>


                                       3
<PAGE>   4

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                      THREE MONTHS ENDED            NINE MONTHS ENDED
                                                                          MARCH 31,                     MARCH 31,
                                                                      1998           1997           1998           1997
                                                                 -------------  -------------  -------------  ---------

                                                                        (AMOUNTS IN MILLIONS, EXCEPT PER SHARE DATA)
<S>                                                                  <C>            <C>           <C>             <C>    
REVENUES
    Services                                                         $ 285.3        $ 246.8       $  781.5        $ 698.1
    Products                                                           117.3           68.3          272.2          232.1
                                                                     -------        -------       --------        -------
        Total revenues                                                 402.6          315.1        1,053.7          930.2
                                                                     -------        -------       --------        -------
COSTS AND EXPENSES
    Cost of services                                                   225.0          193.4          613.5          529.0
    Cost of products                                                    93.3           49.5          211.7          171.0
    Research and development                                             2.2            0.9            3.7            2.8
    Selling, general and administrative                                 91.5           80.3          194.5          182.1
    Amortization of intangibles - acquisition and fresh-start            8.5           22.7           21.1           42.2
    Acquisition-related charges                                         14.0            8.6           14.0           36.0
    Restructuring charges                                                9.2            --             9.2            --
                                                                     -------        -------       --------        -------
        Total costs and expenses                                       443.7          355.4        1,067.7          963.1
                                                                     -------        -------       --------        -------

OPERATING LOSS                                                         (41.1)         (40.3)         (14.0)         (32.9)
                                                                     -------        -------       --------        -------

OTHER (INCOME) EXPENSE
    Interest (income) expense - net                                      3.7            2.6            0.1            4.9
    Other (income) expense - net                                         0.1            0.1           (6.4)          (0.6)
                                                                     -------        -------       --------        -------
        Total other (income) expense                                     3.8            2.7           (6.3)           4.3
                                                                     -------        -------       --------        -------


LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES                    (44.9)         (43.0)          (7.7)         (37.2)
Provision (benefit) for income taxes                                      --          (21.1)          13.4          (18.1)
                                                                     -------        -------       --------        -------

LOSS FROM CONTINUING OPERATIONS                                        (44.9)         (21.9)         (21.1)         (19.1)
INCOME FROM DISCONTINUED OPERATIONS, NET OF TAXES                         --          101.3             --           76.6
                                                                     -------        -------       --------        -------

NET INCOME (LOSS)                                                      (44.9)          79.4          (21.1)          57.5
Dividends and accretion on preferred stock                              (3.5)          (3.6)         (10.6)         (10.6)
                                                                     -------        -------       --------        -------

NET INCOME (LOSS) APPLICABLE TO COMMON STOCKHOLDERS                  $ (48.4)       $  75.8       $  (31.7)       $  46.9
                                                                     =======        =======       ========        =======

PER SHARE AMOUNTS
    Basic
      Continuing operations                                          $ (1.22)       $ (0.69)      $  (0.82)       $ (0.81)
      Discontinued operations                                             --           2.74             --           2.09
                                                                     -------        -------       --------        -------
        Net income (loss) per share                                  $ (1.22)       $  2.05       $  (0.82)       $  1.28
                                                                     =======        =======       ========        =======
    Diluted
      Continuing operations                                          $ (1.22)       $ (0.69)      $  (0.82)       $ (0.81)
      Discontinued operations                                             --           2.74             --           2.09
                                                                     -------        -------       --------        -------
        Net income (loss) per share                                  $ (1.22)       $  2.05       $  (0.82)       $  1.28
                                                                     =======        =======       ========        =======

SHARES USED TO COMPUTE PER SHARE AMOUNTS
    Basic                                                               39.8           37.0           38.7           36.8
    Diluted                                                             39.8           37.0           38.7           36.8
</TABLE>

               See notes to the consolidated financial statements.


                                       4
<PAGE>   5

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                       NINE MONTHS ENDED
                                                                           MARCH 31,
                                                                       1998         1997
                                                                      ------       ------
                                                                     (DOLLARS IN MILLIONS)
        <S>                                                           <C>         <C>      
        OPERATING ACTIVITIES
          Loss from continuing operations                             $ (21.1)    $  (19.1)
          Depreciation                                                   49.0         50.3
          Amortization                                                   23.3         44.3
          Gain on asset sales                                            (6.5)          --
          Non-cash provision (benefit) for income taxes                   9.7        (21.9)
          Non-cash compensation expense                                    --         36.0
          Acquisition-related charges                                    14.0          5.5
          Other restructuring charges                                     9.2           --
          Payments for acquisition-related charges                      (14.9)       (18.7)
          Payments for restructuring charges                             (1.9)        (4.8)
                                                                      -------     --------
                                                                         60.8         71.6
                                                                      -------     --------
        CHANGES IN OTHER ACCOUNTS AFFECTING OPERATIONS
          Accounts receivable                                           (11.7)        (5.5)
          Inventories                                                     3.2          4.1
          Other current assets                                           (4.0)         1.0
          Accounts payable and other current liabilities                (36.8)       (43.2)
          Other                                                          (3.6)         2.9
                                                                      -------     --------
          Net changes in other accounts affecting operations
                                                                        (52.9)       (40.7)
                                                                      -------     --------
                                                                          7.9         30.9

          Net proceeds from sale of discontinued  operations               --        250.5
          Cash used in discontinued operations                           (8.6)       (35.8)
                                                                      -------     --------

              Cash provided by (used in) operations                      (0.7)       245.6
                                                                      -------     --------

        INVESTING ACTIVITIES
          Depreciable assets                                            (54.3)       (34.2)
          Proceeds from asset sales                                      13.9          5.6
          Business acquisitions, net of cash acquired                    25.1       (169.9)
          Other                                                          (0.4)        (4.0)
                                                                      -------     --------
              Cash used in investing activities                         (15.7)      (202.5)
                                                                      -------     --------

        FINANCING ACTIVITIES
          Increase (decrease) in short-term borrowings                   20.5         (0.3)
          Proceeds from stock plans                                       8.4          5.2
          Dividends paid on preferred stock                             (10.0)       (10.1)
          Other                                                          (1.9)         --
                                                                      -------     -------
              Cash provided by (used in) financing activities
                                                                         17.0         (5.2)
                                                                      -------     --------

        Effect of changes in foreign exchange rates on cash              (4.1)        (1.6)
                                                                      -------     --------

        DECREASE IN CASH AND EQUIVALENTS                                 (3.5)        36.3
        CASH AND EQUIVALENTS AT BEGINNING OF PERIOD                     242.2        175.3
                                                                      -------     --------
        CASH AND EQUIVALENTS AT END OF PERIOD                         $ 238.7     $  211.6
                                                                      =======     ========
</TABLE>

               See notes to the consolidated financial statements.


                                       5
<PAGE>   6

                    WANG LABORATORIES, INC. AND SUBSIDIARIES
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
                                 March 31, 1998

NOTE A - BASIS OF PRESENTATION (RESTATED)

The financial information included herein has not been audited. However, in the
opinion of management, all material adjustments necessary for a fair
presentation of the results for the periods presented have been reflected and
consist only of normal recurring accruals, except for acquisition-related and
other special charges recorded in the three and nine month periods ended March
31, 1998 and 1997.

The accompanying financial information should be read in conjunction with the
consolidated financial statements and notes thereto contained in the Company's
Annual Report on Form 10-K filed with the Securities and Exchange Commission for
the fiscal year ended June 30, 1997.

The Company completed the purchase of Olsy ("Olsy"), the wholly-owned
information technology ("IT") solutions and service subsidiary of Olivetti
S.p.A. ("Olivetti") on March 17, 1998, except for Olivetti Corporation of Japan
("OCJ"), Olsy's subsidiary in Japan, which was not completed until April 7,
1998. Cash of $39.6 million was deposited in escrow and was paid to Olivetti
upon completion of the purchase of OCJ. This cash deposit is reported in Other
noncurrent assets at March 31, 1998. Accordingly, the Company's Consolidated
Statements of Operations and of Cash Flows include the results of Olsy since
March 17, 1998, except for the results of OCJ. The Company also acquired a 19.9%
interest in Olivetti Ricerca, the Italian consortium supplying research and
development services to both the IT and telecom sectors. The investment is
recorded in Other noncurrent assets.

The Company completed the sale of its software business unit to Eastman Kodak
Company ("Kodak") on March 17, 1997. The historical results of this business
unit have been reported as discontinued operations in the Company's Consolidated
Statements of Operations for the periods presented.

The Company completed the purchase of I-NET, Inc. ("I-NET") on August 29, 1996.
The Company's Consolidated Statements of Operations and of Cash Flows include
the results of I-NET since acquisition.

Certain amounts in the prior year periods have been reclassified to conform to
current presentations.

Restatement Related to Valuation of Olsy Consideration - Common Stock and Stock
Appreciation Rights:

Pursuant to discussions with the Securities and Exchange Commission ("SEC"), the
Company revised the value of the 8.75 million shares of common stock (of which
1.5 million are to be delivered upon shareholder approval) and the 5.0 million
Stock Appreciation Rights ("SARs") issued to Olivetti as part of the
consideration for Olsy (see Note B). The value of the shares previously recorded
was based on the market value of the Company's common stock, discounted by 35%
to reflect the restrictions contained in the Stock Purchase Agreement between
the Company and Olivetti. The Company has adjusted the value to reflect a
discount of 20% of a revised calculation of market value. The value of the
common stock used to calculate the value of the SARs has been revised consistent
with the revised value per share of the common stock. Accordingly, $41.0 million
of net adjustments were recorded as additional paid-in capital, with a
corresponding increase to intangible assets.


                                       6
<PAGE>   7

                    WANG LABORATORIES, INC. AND SUBSIDIARIES
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
                                 March 31, 1998

NOTE A (Continued)

The effect of the restatement related to the change in value for the common
stock and SAR's resulted in the following impact on the Company's financial
position at March 31, 1998:

<TABLE>
<CAPTION>
                                                               March 31,
                                                                 1998
                                                               ---------

<S>                                                            <C>    
Intangible assets, net, as previously reported                 $ 409.6

Adjustment related to valuation of consideration
  issued for Olsy                                                 41.0
                                                               -------

Restated                                                       $ 450.6
                                                               =======

Capital in excess of par, as previously reported               $ 484.0

Adjustment related to valuation of consideration
  issued for Olsy                                                 41.0
                                                               -------

Restated                                                       $ 525.0
                                                               =======
</TABLE>

In February 1997, the Financial Accounting Standards Board issued Statement No.
128, "Earnings Per Share", which is required to be adopted for financial
statements issued for periods ending after December 15, 1997. In accordance with
this Statement, the Company has changed the method previously used to compute
earnings per share and has restated prior periods. Basic earnings per share is
calculated based on the weighted average number of common shares outstanding,
including approximately 2.6 million shares yet to be distributed by the
Disbursing Agent appointed under the Company's Reorganization Plan. In addition,
diluted earnings per share includes the effect of stock options and warrants,
when dilutive. Income (loss) from continuing operations, for purposes of
calculating basic and diluted earnings per share, has been adjusted by
cumulative dividends and accretion related to the Company's preferred stock.

NOTE B - BUSINESS ACQUISITIONS AND ACQUISITION-RELATED CHARGES (RESTATED)

OLSY

On March 17, 1998, the Company completed the purchase of Olsy, the wholly-owned
information technology solutions and service subsidiary of Olivetti, except for
OCJ, which was not completed until April 7, 1998 (see Note A). The Company also
acquired a 19.9% interest in Olivetti Ricerca, the Italian consortium supplying
research and development services to both the IT and telecom sectors. Olsy's
revenues for the calendar year ended December 31, 1997 were approximately $2.4
billion.

In consideration for Olsy, the Company paid Olivetti $68.6 million in cash;
8,750,000 shares of common stock (of which 1,500,000 are to be delivered upon
shareholder approval) with a value of $197.2 million at the time of issuance;
5,000,000 stock appreciation rights ("SARs") which give Olivetti value for the
increase in the market price of the Company's common stock above $30.00 per
share at any time from March 2001 to March 2005 and are redeemable in cash or
common stock at the Company's election; and the potential for an additional
amount (an "earnout") of up to $56.0 million payable in the year 2000, subject
to meeting mutually-agreed performance targets for the calendar years 1998 to
1999. The earnout will be recorded at the time it becomes probable that a
payment will be required and the amount can be reasonably estimated.


                                       7
<PAGE>   8

                    WANG LABORATORIES, INC. AND SUBSIDIARIES
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
                                 March 31, 1998

NOTE B (Continued)

The acquisition was accounted for using the purchase method of accounting in
accordance with Accounting Principles Board No. 16, "Business Combinations"
("APB 16"). Under APB 16, purchase price allocations are made to the assets
acquired and the liabilities assumed based on their respective fair values. The
value of the shares was recorded at a discount of 20% of the market value of the
Company's common stock. The value of the SARs was recorded based on the
historical and implied volatility of the common stock, considering both the
minimum guaranteed price and the restrictions on exercise inherent in the SARs.
These values were determined by independent valuations. The shares are not
registered and are subject to a three-year restriction period.

A summary of the acquisition, which excludes OCJ, follows (in millions):

<TABLE>
   <S>                                                                <C>     
   Cash, excluding OCJ escrow, including transaction costs            $   47.0
   Common stock and stock equivalents                                    197.2
   Stock appreciation rights                                              32.5
                                                                      --------

   Total consideration                                                   276.7

   Estimated fair value of net tangible assets
   acquired                                                              130.3
                                                                      --------

   Excess of purchase price over net tangible
   assets acquired                                                    $  146.4
                                                                      ========
</TABLE>

The excess of the purchase price over the fair value of the net assets acquired
was $146.4 million and has been recorded based on a preliminary purchase price
allocation. Finalization of the allocation of the purchase price to assets
acquired and liabilities assumed is subject to appraisals, valuations,
evaluations and other analysis of the fair value of assets acquired and
liabilities assumed, including the anticipated valuation of certain purchased
research and development activities. Amortization for the fourteen day period
subsequent to the acquisition was $0.2 million calculated on a straight line
basis over an estimated useful life of 25 years.

The Company is repositioning itself to be the leading global desktop and network
services company and estimates that expenditures of as much as $380 million will
be required over the next 24 to 36 months in connection with the integration and
rightsizing of both Olsy and Wang. Of that total, approximately $275 million is
estimated to relate to organizational redundancies, $75 million related to
facilities, and $30 million related to systems and other costs. Under certain
conditions, costs related to the acquired Olsy business will be accounted for as
an additional cost of the acquisition at the time the formal plan of
restructuring is completed. Integration-related costs attributable to Wang will
be accounted for as charges to operations in the periods they are determined.

In connection with the acquisition, on March 13, 1998, the Company entered into
a multi-currency, revolving credit facility with Bankers Trust Company ("BTC")
and certain other financial institutions. The five-year facility provides
borrowings up to $500.0 million, including $200.0 million for letters of credit.
Interest on the borrowings is based on the LIBOR rate plus 0.75% to 1.50%,
depending on the Company's leverage ratio. Fees and expenses associated with the
new facility amounted to $7.5 million, approximately $3.5 million of which has
been charged to interest expense in the March quarter of 1998 associated with
that portion of the facility used to replace the existing $225 million facility.
The BTC agreement contains various financial covenants, including covenants
relating to the Company's operating results, working capital, net worth and
indebtedness. In addition to providing financing for the Olsy acquisition, the
credit facility will be used for general corporate purposes. As of March 31,
1998, borrowings of $68.6 million and letters of credit aggregating $8.8 million
were outstanding under the agreement. The financing is secured by substantially
all of the Company's domestic assets and partial pledges of selected
international subsidiaries.


                                       8
<PAGE>   9

                    WANG LABORATORIES, INC. AND SUBSIDIARIES
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
                                 March 31, 1998

NOTE B (Continued)

I-NET

On August 29, 1996, the Company completed the purchase of all of the outstanding
shares of I-NET. In consideration for the shares of I-NET the Company paid
$100.2 million in cash and issued one-year, interest-free notes in the total
amount of $64.5 million. The Company discounted the notes at a rate of 8.0%, to
$59.7 million for accounting purposes, and increased the principal balance
through charges to interest expense through the settlement date.

Through September 1997, the Company paid $36.3 million to the holders of the
notes, including $2.2 million of interest. In accordance with the terms of a
final settlement of the notes reached November 13, 1997, the Company paid an
additional $14.9 million, including $1.6 million of accrued interest, to the
selling shareholders. The balance of $13.3 million was reversed in the three
months ended December 31, 1997, of which $1.2 million was recorded as a
reduction of interest expense and $12.1 million was recorded as an adjustment of
the original purchase price.

NOTE C - SPECIAL CHARGES

During the quarter ended March 31, 1998, the Company recorded special charges of
$55.7 million including $23.2 million for integration and restructuring-related
costs, $10.3 million for advertising related to the Olsy acquisition, $7.3
million related to reductions in the carrying value of certain assets, $3.5
million of bank fees and $11.4 million of other costs.

The integration and restructuring-related costs of $23.2 million were provided
after certain actions had been identified, quantified and approved. Additional
charges are anticipated as the balance of the plan actions are quantified. The
integration and restructuring charges recorded in the March quarter consist of
the following (in millions):

<TABLE>
<CAPTION>
              <S>                                            <C>    
              Workforce-related                              $  13.0
              Depreciable assets and other                       0.9
              Facilities                                         9.3
                                                             -------
                 Total                                       $  23.2
                                                             =======
</TABLE>

These charges were recorded as of March 31, 1998 and were based upon best
estimates associated with approved actions through that date. The
facilities-related charges for the Company's excess facilities were recorded to
recognize the lower of the amount of the remaining lease obligations, net of any
sublease rentals, or the expected lease settlement costs. These costs have been
estimated only from the time when the space is expected to be vacated and only
if there are no plans to utilize the facility in the future. Costs incurred
prior to that time will be charged to operations. Depreciable asset-related
charges were provided to recognize, at net realizable value, the write-down to
disposal value of existing assets. Workforce-related charges, consisting
principally of severance costs, were recorded based on specific identification
of employees to be terminated, along with their job classifications or functions
and their locations. Cash requirements to complete these initial integration and
restructuring initiatives are estimated to approximate $8 million for the
remainder of fiscal 1998 and $15 million thereafter, although under certain
circumstances, the actual payment of termination costs may extend beyond that
date.


                                       9
<PAGE>   10

                    WANG LABORATORIES, INC. AND SUBSIDIARIES
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
                                 March 31, 1998

NOTE D - EARNINGS PER SHARE

<TABLE>
<CAPTION>
                                                                      THREE MONTHS ENDED          NINE MONTHS ENDED
                                                                           MARCH 31,                  MARCH 31,
                                                                       1998         1997           1998         1997
                                                                      -------      -------       -------       -------
                                                                           (IN MILLIONS EXCEPT PER SHARE DATA)
          <S>                                                         <C>          <C>           <C>           <C>     
          Numerator:                                                
             Loss from continuing operations                          $ (44.9)     $ (21.9)      $ (21.1)      $ (19.1)
             Dividends and accretion on the                         
               Series A Preferred Stock                                  (1.2)        (1.2)         (3.6)         (3.6)
             Dividends on the Series B Preferred Stock                   (2.3)        (2.4)         (7.0)         (7.0)
                                                                      -------      -------       -------       -------
             Numerator for basic and diluted earnings               
               per share - loss from continuing                     
               operations available to common                       
               shareholders                                           $ (48.4)     $ (25.5)      $ (31.7)      $ (29.7)
                                                                      =======      =======       =======       =======
                                                                    
          Denominator:                                              
             Denominator for basic and diluted earnings             
               per share - weighted average shares                       39.8         37.0          38.7          36.8
                                                                      =======      =======       =======       =======
                                                                    
          Basic Earnings per Share - Continuing Operations            $ (1.22)     $ (0.69)      $ (0.82)      $ (0.81)
                                                                      =======      =======       =======       =======
          Diluted Earnings per Share -  Continuing Operations         $ (1.22)     $ (0.69)      $ (0.82)      $ (0.81)
                                                                      =======      =======       =======       =======
</TABLE>

Options to purchase approximately 6,680,000 shares of common stock and warrants
to purchase approximately 7,500,000 shares of common stock were excluded from
the computation of diluted earnings per share as their effect would be
antidilutive.

In connection with the sale of its software business to Kodak, the company
issued to Microsoft a warrant to purchase 1,000,000 shares of common stock at an
exercise price of $23.00 per share. The warrant became exercisable 90 days after
the closing and expires on the redemption date of the Series A Preferred Stock.
If and when exercised, the warrant will be settled on a net basis in shares of
common stock. The warrant was excluded from the computation of diluted earnings
per share as its effect would be antidilutive.

In connection with the acquisition of Olsy, the Company issued to Olivetti
5,000,000 stock appreciation rights ("SARs"). Each right entitles Olivetti to
receive from the Company an amount equal to the higher of: (a) $4.00 or (b) the
excess over $30.00 (the "strike price") of the fair market value per share of
Common Stock on the date of exercise. The Company may pay such amount in either
cash or shares of common stock at its option. The SARs can be exercised any time
from March 2001 to March 2005. The SARs were excluded from the computation of
diluted earnings per share as their effect would be antidilutive.

For additional disclosures regarding the Series A and Series B Preferred Stock,
see the discussion of Superior Rights of Preferred Stock in the Risks and
Uncertainties section of Management's Discussion and Analysis of Financial
Condition and Results of Operations.

NOTE E - MICROSOFT ALLIANCE

On March 23, 1998, the Company and Microsoft Corporation announced an expansion
of their strategic alliance. The Company will significantly extend its service
capacity by training and certifying 2,500 professionals as Microsoft Certified
Systems Engineers and Microsoft Certified Solution Developers. To help customers
design and deploy Microsoft networked technology solutions, the Company will
open two Centers of Excellence, one at its new worldwide headquarters in
Billerica, Massachusetts, and one in Italy. The centers will showcase enterprise
solutions based on Microsoft technologies and the Company's integrated services.
In addition, the Company will establish Technology Integration Labs to design
and test customer solutions based on Microsoft technology and will lead with
Microsoft's enterprise products in customer accounts.

Under the terms of the agreement, Microsoft will fund the costs associated with
this program through an interest-free loan. These costs are expected to
approximate $25 million over the next three years. The loan will be repaid in
equal installments over five years, with the first payment due in 2001.


                                       10
<PAGE>   11

                    WANG LABORATORIES, INC. AND SUBSIDIARIES
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
                                 March 31, 1998

NOTE F - SUBSEQUENT EVENTS

On April 7, 1998, the Company completed the purchase of OCJ, Olsy's subsidiary
in Japan. The cash payment of $39.6 million to Olivetti attributable to the
purchase of the Japanese subsidiary was held in an escrow account until the
transaction was completed. Accordingly, the results of OCJ are not included in
the Company's Consolidated Statements of Operations and of Cash Flows for the
three and nine months ended March 31, 1998.

On April 22, 1998, the Company's Board of Directors adopted a Shareholders
Rights Agreement. The description and terms of the Rights are set forth in a
Rights Agreement including all exhibits thereto, between the Company and
American Stock Transfer & Trust Company as Rights Agent.


                                       11
<PAGE>   12

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                       CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

This discussion includes certain forward-looking statements about matters such
as the Company's revenue, expected expenses, operating results and the need for
additional investment. Any such statements are subject to normal business risks
and uncertainties that could cause the actual results or needs to differ from
those described herein. For a further discussion of the various risks affecting
the business, refer to "Risks and Uncertainties" appearing at the end of this
Management's Discussion and Analysis of Financial Condition and Results of
Operations.

BASIS OF PRESENTATION

On March 17, 1998, the Company completed the purchase of Olsy ("Olsy"), the
wholly-owned information technology ("IT") solutions and service subsidiary of
Olivetti S.p.A. ("Olivetti"), except for Olivetti Corporation of Japan ("OCJ"),
Olsy's subsidiary in Japan, which was not completed until April 7, 1998.
Accordingly, the Company's Consolidated Balance Sheet and Statements of
Operations and of Cash Flows include the results of Olsy since March 17, except
the results of the OCJ. Olsy develops, implements and manages IT solutions for
large public and private corporate customers, mainly in banking, the public
authorities and utilities sector, and retail. The company provides a broad range
of services, including application development and systems integration, network
integration and management services and distributed IT management services to a
worldwide customer portfolio. Olsy employs more than 12,000 individuals in more
than 40 countries, with annual revenues of approximately $2.4 billion in
calendar 1997.

In connection with the Company's acquisition of Olsy, the management of the
Company has adopted the name Wang Global. The change is subject to shareholder
approval. During the interim, the Company's legal name will continue to be Wang
Laboratories, Inc.; however, the Company will conduct its business as Wang
Global.

On March 17, 1997, the Company completed the sale of its software business unit
to Eastman Kodak Company ("Kodak"). The historical results of the software
business have been reported as discontinued operations in the Company's
Consolidated Statements of Operations and of Cash Flows for the three and nine
month periods ended March 31, 1997. The following discussion addresses the
results of the Company's continuing operations.

The results of operations for the periods reported are not necessarily
indicative of those that may be expected for the full fiscal year.

RESULTS OF CONTINUING OPERATIONS

THREE AND NINE MONTHS ENDED MARCH 31, 1998 COMPARED TO THREE AND NINE MONTHS
ENDED MARCH 31, 1997

OVERVIEW

For the three months ended March 31, 1998, the Company reported revenues of
$402.6 million, a 27.8% increase compared to the same prior year period. The
increase is attributable to growth in the Company's network services revenues
and the inclusion of Olsy's results for the fourteen days subsequent to
consummation of the transaction, partially offset by the anticipated decline in
proprietary revenues. Revenues for the three months ended March 31, 1998, at
constant currency, would have been approximately $8 million higher.

Revenues were $1,053.7 million for the nine months ended March 31, 1998, a 13.3%
increase from the same prior year period, when revenues of $930.2 million were
reported.

The Company reported an operating loss of $41.1 million for the three months
ended March 31, 1998, compared to an operating loss of $40.3 million for the
three months ended March 31, 1997. Operating losses for the nine months ended
March 31, 1998 and 1997 were $14.0 million and $32.9 million, respectively.


                                       12
<PAGE>   13

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

The operating loss for the three and nine month periods ended March 31, 1998
relates primarily to nonrecurring charges of $52.2 million recorded during the
March quarter. These costs include $23.2 million of Wang integration and
restructuring costs, $10.3 million for advertising related to the Olsy
acquisition, $7.3 million related to reductions in the carrying value of certain
assets and $11.4 million for other costs. The $52.2 million is recorded in the
Consolidated Statements of Operations as follows: $27.2 million in Selling,
general and administrative expenses; $1.8 million in Amortization of
intangibles; $12.5 million in Acquisition-related charges and $10.7 million in
Restructuring charges.

The operating loss for the three and nine months ended March 31, 1997 includes
$52.5 million of costs associated with the Company's organization of its then
ongoing services business around four global service delivery units after the
sale of it software business on March 17, 1997. Of that total, $13.3 million
resulted from the sale of the software business, $15.2 million was for
organizational realignment and reductions in the G&A infrastructure, $19.0
million related to reductions in the carrying value of certain assets (including
$14.4 million of intangible assets determined to be impaired) and $5.0 million
was for other charges. The writedown of the impaired intangible assets is
included in the $22.7 million of amortization of acquired and fresh-start
intangible assets reported in the Statement of Operations for the three months
ended March 31, 1997. The Company had also recorded acquisition-related charges
of $27.4 million in the three months ended September 30, 1996.

Excluding these charges, the Company would have reported operating income of
$11.1 million and $38.2 million in the three and nine months ended March 31,
1998, and operating income of $12.2 million and $47.0 million, respectively, in
the same prior year periods. Income before taxes for the three month periods
ended March 31, 1998 and 1997, was $10.8 million and $9.5 million, respectively.

Excluding the charges in fiscal 1998, the decline in operating income for the
nine month period is primarily attributable to the anticipated decline in
higher-margin revenues from proprietary products and services and the increase
in the mix of lower-margin revenues from desktop and network products and
services, principally from the acquisition of I-NET. The Company anticipates
that the shift in revenue mix and the decline in proprietary revenues will
continue and will contribute to the downward pressure on consolidated gross
margins.

EBITDA (earnings before interest, income taxes, depreciation and amortization)
from continuing operations was $36.5 million and $36.2 million in the three
month periods ended March 31, 1998 and 1997, respectively. EBITDA can be
calculated differently from one company to the next, so this measure may not be
comparable to EBITDA reported by other companies. EBITDA is calculated for the
three months ended March 31, 1998 by adjusting the operating loss of $41.1
million for nonrecurring charges of $52.2 million, depreciation and amortization
expenses not included in the nonrecurring charges of $18.1 million and $7.4
million, respectively, and other expense of $0.1 million not reflected in the
nonrecurring charges. EBITDA is calculated for the three months ended March 31,
1997 by adjusting the operating loss of $40.3 million for nonrecurring charges
of $52.5 million, depreciation and amortization expenses not included in the
nonrecurring charges of $15.2 million and $8.9 million, respectively, and other
expense of $0.1 million not reflected in the nonrecurring charges.

EBITDA from continuing operations for the nine months ended March 31, 1998 and
1997 was $115.1 million and $122.7 million, respectively. EBITDA for the nine
months ended March 31, 1998 is calculated by adjusting the operating loss of
$14.0 million for nonrecurring charges of $52.2 million, depreciation and
amortization expenses not included in the nonrecurring charges of $49.0 million
and $21.5 million, respectively, and other income of $6.4 million not reflected
in the nonrecurring charges. EBITDA is calculated for the nine months ended
March 31, 1997 by adjusting the operating loss of $32.9 million for nonrecurring
charges of $79.9 million, depreciation and amortization expenses not included in
the nonrecurring charges of $45.5 million and $29.7 million, respectively, and
other income of $0.5 million not reflected in the nonrecurring charges.

For the nine months ended March 31, 1998, cash used in operating and investing
activities was $0.7 million and $15.7 million, respectively. Cash provided by
financing activities was $17.0 million.


                                       13
<PAGE>   14

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

For the nine months ended March 31, 1997, cash provided by operations was $245.6
million. Cash used in investing and financing activities was $202.5 million and
$5.2 million, respectively.

The Company periodically evaluates the carrying value of intangible assets to
determine if impairment exists based upon estimated undiscounted future cash
flows. The impairment, if any, is measured by the difference between carrying
value and estimated discounted future cash flows and is charged to expense in
the period identified. Decline rates of traditional product and service revenues
may be higher than the Company's historical experience. If that proves to be
true, then margins in traditional products and services will also come under
pressure. As discussed in prior periods, margins in commercial outsourcing are
likely to be under higher than anticipated competitive pressure. Taken together,
it is possible that the full amount of certain intangible assets acquired in
connection with the acquisition of I-NET and Bull may not ultimately be
recoverable. In light of these current trends in market demand, the Company has
undertaken an assessment of whether the projected future cash flows of these
businesses will be sufficient to recover the carrying amount of the related
intangible assets. The Company expects to complete this analysis in the fourth
quarter. If recent trends continue, forecasted cash flows may be insufficient to
recover the intangible assets, and accordingly, the Company would be required to
recognize an impairment charge by reducing the carrying amount of the intangible
assets to their then estimated fair values. Such a charge, if required, would be
material.

REVENUES

Revenues from proprietary sources (i.e., sales and service of proprietary VS and
GCOS products) declined at a rate of 27.8% for the three month period ended
March 31, 1998, compared to the same prior year period. Proprietary revenues
declined 26.1% for the nine month period ended March 31, 1998, compared to the
same prior year period. The Company expects that revenues from proprietary
sources will decline at a rate approximating 25% per year on a constant currency
basis, but that rate may accelerate as the Company's customers make systems
decisions regarding Year 2000 compliance. Additionally, from one period to the
next, the rate of decline could be highly variable.

Services revenues increased by 15.6%, to $285.3 million for the three month
period ended March 31, 1998, compared to $246.8 million in the same prior year
period. Services revenues for the nine months ended March 31, 1998 were $781.5
million, a 12.0% increase compared to $698.1 million for the nine months ended
March 31, 1997. Network services revenues increased by 29.8%, to $242.1 million
in the three months ended March 31, 1998, compared to $186.5 million in the
three months ended March 31, 1997. Network services revenues increased by 28.0%,
to $640.5 million, in the nine months ended March 31, 1998, compared to $500.2
million in the nine months ended March 31, 1997. The nine month increase in
network services revenues was partially attributable to the acquisitions of
I-NET and Olsy. Proprietary services revenues decreased by 28.4%, to $43.2
million, for the three months ended March 31, 1998, compared to the three months
ended March 31, 1997. Proprietary services revenues decreased by 28.7%, to
$141.0 million, for the nine months ended March 31, 1998, compared to $197.9
million for the same prior year period.

Product revenues increased by 71.7%, to $117.3 million, for the three months
ended March 31, 1998 compared to the same prior year period. Proprietary product
sales declined by $3.5 million, or 25.2%, to $10.4 million for the three months
ended March 31, 1998, compared to the three months ended March 31, 1997. The
decline in proprietary product sales to $38.5 million for the nine months ended
March 31, 1998, compared to the nine months ended March 31, 1997 was $6.6
million, or 14.6%. Network product and other product sales nearly doubled, to
$106.9 million for the three months ended March 31, 1998, compared to $54.4
million in the same period of the prior year. Network product and other product
sales for the nine months ended March 31, 1998 were $233.7 million, an increase
of $46.7 million, or 25.0%, compared to the nine months ended March 31, 1997.
This increase was primarily attributable to the acquisition of Olsy.


                                       14
<PAGE>   15

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

GROSS MARGIN

Services gross margins for the three and nine months ended March 31, 1998 were
21.1% and 21.5%, respectively, compared to 21.6% and 24.2%, respectively, for
the three and nine month periods ended March 31, 1997. The gross margin percent
for the three and nine month periods was negatively affected by the result of
the increase in lower-margin maintenance revenues on multi-vendor services
products, the decline in higher-margin revenues from proprietary maintenance
contracts, the continuing dilutive impact of certain low margin commercial
contracts from I-NET and Olsy's lower margin structure, partially offset by the
favorable margin impact from the licensing and sale of $4.6 million of
intellectual property. Although it is anticipated that these factors will
continue to exert pressure on services gross margin, the Company believes that
the effects can be managed by the continuing implementation of cost reduction,
integration and consolidation initiatives.

Product gross margin for the three months ended March 31, 1998 decreased to
20.5%, from 27.5% in the comparable prior year period. Product gross margin for
the nine months ended March 31, 1998 decreased to 22.2%, compared to 26.3% for
the nine months ended March 31, 1997. This decrease is primarily the result of
the decline in proprietary product sales, which have historically higher margins
than the margins on resold client-server products, coupled with Olsy's lower
margin structure. The Company anticipates that the decline in proprietary
product revenues will continue to exert downward pressure on gross margin.

RESEARCH AND DEVELOPMENT EXPENSES

Research and development costs increased by $1.3 million for the three months
ended March 31, 1998, from $0.9 million in the comparable prior year period.
Research and development costs were $3.7 million for the nine months ended March
31, 1998, an increase of $0.9 million from the nine months ended March 31, 1997.
Research and development costs include amounts spent by Olsy since the
acquisition and development by OliRicerca (a minority investee company) under
contract with Wang Global. The Company's modest level of research and
development spending is primarily related to continuing support for its
proprietary VS products and specialized client server products sold to the U.S.
government and to the development of software technology for the banking
industry.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses for the three months ended March
31, 1998, increased by $11.2 million, or 13.9%, to $91.5 million. This increase
is attributable to the inclusion of Olsy as well as the inclusion of $27.2
million of special charges, and compares to $80.3 million, including $23.1
million of special charges, in the same prior year period.

Selling, general and administrative expenses in the nine months ended March 31,
1998 were $194.5 million, including $27.2 million of special charges, an
increase of 6.8% compared to selling, general and administrative expenses of
$182.1 million, including $23.1 million for nonrecurring charges, in the same
prior year period.

Special charges recorded in Selling, general and administrative expenses in the
March 1998 quarter included $10.3 million for advertising branding and
positioning initiatives to launch the new combined company, Wang Global, $5.5
million related to reductions in the carrying value of certain assets and $11.4
million for other costs. Special charges of $23.1 million in the March 1997
quarter recorded in Selling, general and administrative expenses included $13.3
million which resulted from the sale of the software business, $8.3 million
related to reductions in the carrying value of certain assets and $1.5 million
for other costs.

Excluding these special charges, selling, general and administrative expenses
would have been $64.3 million, in the three months ended March 31, 1998 compared
to $57.2 million in the same prior year period, and would have been 16.0% and
18.1% of revenues, respectively. Selling, general and administrative expenses
for the nine months ended March 31, 1998 would have been $167.3 million,
compared to $159.0 million in the comparable prior year period, excluding
nonrecurring charges. Selling, general and administrative expenses would have
been 15.9% of revenues and 17.1% of revenues in the nine months ended March 31,
1998 and 1997, respectively, excluding the special charges.

The overall reduction in selling, general and administrative expenses relative
to revenues reflects the results of integration activities initiated in
connection with the Company's recent acquisitions, in addition to other cost
control activities.


                                       15
<PAGE>   16

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

AMORTIZATION

Amortization of acquired intangible assets totaled $8.5 million and $21.1
million in the three and nine months ended March 31, 1998, respectively,
including $0.2 million for intangible assets established as part of the Olsy
acquisition for the fourteen day period, and $1.8 million for the writedown of
intangible assets determined to be impaired. During the prior fiscal year, the
Company eliminated its remaining fresh-start intangible assets following the
sale of its software business unit to Kodak through the recognition of a
deferred tax asset attributable to the realization and expected utilization of
tax net operating loss carryforwards which existed at September 30, 1993.
Amortization of fresh-start and acquired intangible assets in the three months
ended March 31, 1997 was $22.7 million, of which $2.2 million relates to the
implementation of fresh-start reporting, $6.1 million relates to intangible
assets established in connection with business acquisitions and $14.4 million
relates to the writedown of acquired intangible assets determined to be
impaired. Amortization of acquired intangible assets totaled $21.1 million in
the nine months ended March 31, 1998. Amortization of fresh-start and intangible
assets in the nine months ended March 31, 1997 was $42.2 million, of which $9.5
million relates to the implementation of fresh-start reporting, $18.3 million
relates to intangible assets established in connection with business
acquisitions and $14.4 million relates to the writedown of acquired intangible
assets determined to be impaired.

ACQUISITION-RELATED AND RESTRUCTURING CHARGES

Acquisition-related charges of $14.0 million in the three and nine months ended
March 31, 1998 reflect the costs associated with beginning to combine the
operations of the Company and Olsy; charges of $36.0 million in the nine months
ended March 31, 1997 primarily reflect the costs associated with combining the
operations of the Company and I-NET and other business consolidation activities.

Restructuring charges of $9.2 million in the three and nine months ended March
31, 1998 primarily reflect the costs associated with workforce reductions
relative to the declining VS revenue stream. There were no restructuring charges
recorded in the nine months ended March 31, 1997.

INTEREST INCOME AND EXPENSE

Net interest expense of $3.7 million in the three months ended March 31, 1998 is
primarily comprised of $5.6 million of interest expense, including $4.7 million
related to the Company's new Revolving Credit Facility with Bankers Trust
Company ("BTC") of $500 million, and the previous Revolving Credit Facility with
BTC, which was replaced with $225 million from the new facility, and $1.9
million of interest income. This compares to $2.6 million of net interest
expense in the same prior year period . Net interest expense of $0.1 million in
the nine months ended March 31, 1998 was comprised of $6.6 million of interest
income and $6.7 million of interest expense, compared to $4.9 million of net
interest expense in the same prior year period, consisting of $8.8 million of
interest expense and $3.9 million of interest income. Interest expense in the
prior year period principally relates to amounts borrowed under and fees
associated with the previous $225 million Revolving Credit Facility with BTC.
The increase in interest income in the three and nine months ended March 31,
1998, compared to the prior year periods, was primarily due to higher cash
balances resulting from the sale of the Company's software business unit to
Kodak.

OTHER INCOME AND EXPENSE

Net other expense of $0.1 million was reported in each of the three month
periods ended March 31, 1998 and 1997. Net other income of $6.4 million in the
nine months ended March 31, 1998 primarily consisted of a $6.5 million gain
realized in the first quarter of fiscal 1998 on the sale of certain land and
facilities owned by the Company in Billerica, Massachusetts, compared to net
other expense of $0.6 million in the same period of the prior year.

INCOME TAXES

The provision for income taxes in the nine months ended March 31, 1998 was $13.4
million, and included $9.7 million of non-cash expense. The benefit for income
taxes for the nine months ended March 30, 1997 relates to the utilization of
certain foreign net operating loss carryforwards incurred subsequent to the
Company's emergence from Chapter 11.

EMPLOYEES

At March 31, 1998, the Company had approximately 21,900 employees.


                                       16
<PAGE>   17

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

LIQUIDITY AND SOURCES OF CAPITAL

Cash and equivalents were $238.7 million at March 31, 1998, a decrease of $3.5
million from June 30, 1997.

Cash used in operations during the nine months ended March 31, 1998 was $0.7
million, and includes $23.7 million generated from Wang operating activities,
less $15.8 million used by Olsy during the period subsequent to the acquisition
and $8.6 million used for costs associated with prior discontinued operations.

Cash used in investing activities during the nine months ended March 31, 1998
was $15.7 million. $54.3 million was used for capital additions, including $23.8
million for consumable spares and $7.7 million towards the construction of new
facilities, offset by $13.9 million of proceeds on asset sales. Net cash
acquired in connection with the Olsy acquisition was $36.3 million and consists
of $113.3 million acquired less $68.6 million of cash consideration and
transaction costs of $8.4 million.

In connection with the acquisition, on March 13, 1998, the Company entered into
a multi-currency, revolving credit facility with Bankers Trust Company ("BTC")
and certain other financial institutions. The five-year facility provides
borrowings up to $500.0 million, including $200.0 million for letters of credit.
Interest on the borrowings is based on the LIBOR rate plus 0.75% to 1.50%,
depending on the Company's leverage ratio. Fees and expenses associated with the
new facility amounted to $7.5 million, approximately $3.5 million of which has
been charged to interest expense in the March quarter of 1998 associated with
that portion of the facility used to replace the existing $225 million facility.
The BTC agreement contains various financial covenants, including covenants
relating to the Company's operating results, working capital, net worth and
indebtedness. In addition to providing financing for the Olsy acquisition, the
credit facility will be used for general corporate purposes. As of March 31,
1998, borrowings of $68.6 million and letters of credit aggregating $8.8 million
were outstanding under the agreement. The financing is secured by substantially
all of the Company's domestic assets and partial pledges of selected
international subsidiaries.

Cash provided by financing activities was $17.0 million during the nine months
ended March 31, 1998, and consists primarily of net borrowings under the
Revolving Credit Facility with BTC of $68.6 million, principal payments in
connection with the settlement of the notes to the selling stockholders of I-NET
of $47.4 million, cash dividends paid of $10.0 million, less $8.4 million
proceeds from stock plans.

In addition to normal operating activities, capital expenditures and payment of
preferred dividends, the Company estimates that expenditures of as much as $380
million will be required in connection with the integration and rightsizing of
the combined company. The $380 million includes approximately $275 million
related to organizational redundancies, $75 million related to facilities and
$30 million related to systems and other costs. The Company currently estimates
that the cash utilization associated with these expenditures will approximate
$155 million, $155 million and $70 million in calendar years 1998, 1999 and
2000, respectively. The Company estimates that the $380 million will be
recovered through cost savings through calendar year 2000, or an estimated
payback averaging approximately eighteen months.

Additionally, the Company has announced that it will spend an additional $12
million for advertising, branding and positioning initiatives to launch the
newly combined company, Wang Global, and approximately $12 million for the
completion of the construction and fit-up of the Company's new Corporate
headquarters in Billerica, Massachusetts. The estimated total cost of the
construction activities is $20 million, which approximates the cumulative
proceeds, realized or expected to be realized, from the disposition of land and
facilities.

The Company believes that existing cash balances, cash generated from
operations, and borrowing availability under its Revolving Credit Facility will
be sufficient to meet the Company's operational cash requirements as well as the
integration and restructuring initiatives previously discussed, and for pursuing
potential investments, acquisitions and other expansion opportunities. As part
of furthering its business strategy, the Company explores acquisitions and
strategic relationships with other businesses on an on-going basis. One or more
of these opportunities could have an impact on the Company's liquidity through
the use of cash or could involve the issuance of debt or equity securities of
the Company.


                                       17
<PAGE>   18

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

RISKS AND UNCERTAINTIES

Certain statements in this Form 10-Q may be deemed "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 (the
"Act"). The Company desires to take advantage of the safe harbor provisions of
the Act and is including this statement for the express purpose of availing
itself of the protection of the safe harbor with respect to all forward-looking
statements that involve risks and uncertainties. The Company or its
representatives may also make forward looking statements in other written
reports filed with the Securities and Exchange Commission ("SEC"), in materials
delivered to stockholders, in press releases or in oral statements to security
analysts, investors and others. Forward looking statements provide current
expectations of future events based on certain assumptions and include any
statement that does not directly relate to any historical or current fact. Words
such as "anticipates," "believes," "expects," "estimates," "intends," "plans,"
"projects," and similar expressions, may identify such forward-looking
statements. In accordance with the Act, set forth below are cautionary
statements that accompany those forward-looking statements. Readers should
carefully review these cautionary statements as they identify certain important
factors that could cause actual results to differ materially from those in the
forward-looking statements and from historical trends. Such forward-looking
statements may relate to various matters, including, without limitation, the
Company's business, revenue, expenses, profitability, acquisitions,
dispositions, products, services, intellectual property, expenses, labor
matters, effective tax rate and operating and capital requirements. The
following cautionary statements are not exclusive and are in addition to other
factors discussed elsewhere in the Company's filings with the SEC and in
materials incorporated therein by reference.

      IMPLEMENTATION OF BUSINESS STRATEGY. The Company's business strategy is to
increase the revenues and margins it realizes from providing network services
and products to customers and clients and to build upon that growth through
acquisitions and alliances with other companies. The Company's ability to
implement successfully this strategy over the long term, and the ultimate
success of this strategy and the achievement of sustained profitable growth is
uncertain and subject to a broad range of variables and contingencies, many of
which are beyond the Company's control. The Company may not be able to achieve
the revenue growth it is seeking as a result of an inability to obtain new
customer contracts, recruit and retain required skilled personnel or the
inability to deliver the required services in a timely and satisfactory manner
to customers. In addition, there can be no assurance that the Company will be
able to implement strategic relationships or acquisitions, or, if entered into,
that such strategic relationships or acquisitions will in fact further the
implementation of the Company's business strategy. The Company's existing
strategic relationships with Microsoft Corporation, Dell Computer Corporation
and Cisco Systems, Inc. are subject to a variety of uncertainties, including
possible evolutions in technology, business relationships or strategic plans of
the parties which may, in the future, result in the termination of, or a change
in the nature of or in the expectations with respect to, such strategic
relationships. The Company's relationships with Microsoft and Cisco also
includes certain contractual obligations, which, if not satisfied, could allow
Microsoft and Cisco, respectively, to terminate all or a portion of the
relationships.

      Currently, a significant portion of the Company's revenues and gross
margins are attributable to the servicing, upgrading and enhancement of its
installed base of VS and other proprietary systems. The Company expects revenues
from proprietary sources, including the acquired Bull proprietary product and
service revenue streams, to decline at a rate approximating 25% per year on a
constant currency basis, but that rate may accelerate as the Company's customers
make systems decisions regarding Year 2000 compliance. Additionally, from one
period to the next, the decline rate could be highly variable. As the Company's
proprietary revenues decline, the loss of individual customers will have an
increasingly significant effect on the rate of decline for any particular
measurement period. The Company's continued growth is predicated on the business
strategy described above (including the acquisition of new customer service and
network integration businesses) more than offsetting the decline in revenues and
gross margins from proprietary sources. There can be no assurance that delays or
difficulties in the implementation of the Company's strategy, or a higher than
anticipated decline in revenues and gross margins from proprietary sources will
not adversely impact the Company's results of operations or the price of its
equity.


                                       18
<PAGE>   19

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

      RISKS OF NEWLY ACQUIRED BUSINESSES. In March and April 1998, the Company
completed its acquisition of the wholly-owned IT solutions and services business
of Olivetti ("Olsy") from the Olivetti Corporation. The transaction more than
doubled the revenue and number of employees of the Company. The Company will
confront a number of risks as it operates the Olsy business and integrates it
with the Company's existing business. As with any significant acquisition or
merger, the Company confronts challenges in retaining employees, customer
relationships, synchronizing service delivery systems and business processes,
and integrating logistics, marketing, and product offerings to achieve greater
efficiencies. Moreover, the Company may be unable to implement all anticipated
cost savings in the Olsy business. Finally, there can be no assurance that the
acquisition of Olsy or any of the Company's other acquisitions or strategic
alliances will result in long-term benefits to the Company, or that the Company
and its management will be able to effectively assimilate and manage the
business of such acquired companies. The Company continues to evaluate such
opportunities regularly, and one or more other transactions could occur at any
time.

      The transfer of Company shares to Olivetti as part of the purchase price
for Olsy increases the risk that the Company's use of its net operating loss may
be limited in the future. Federal tax rules impose an annual limitation on the
use of a net operating loss when the change of ownership of shares in a
corporation exceeds a certain limit. The transfer of Company shares to Olivetti
brings the aggregate change of ownership close to, but not in excess of, that
stated limit. Other unforeseen changes of ownership may push the aggregate
change of ownership over the stated limit. The Company believes that even if the
annual limitation on the use of its net operating loss were imposed, such
limitation would be of no consequence as the projected annual limitation on the
use of a net operating loss exceeds the projected federal taxable income of the
Company.

      DEPENDENCE ON KEY PERSONNEL. The Company depends to a significant extent
on key management personnel and technical employees. The Company's growth and
future success will depend in large part on its ability to attract, motivate and
retain highly qualified personnel, particularly, trained and experienced
technical professionals capable of providing sophisticated network and desktop
outsourcing and integration services. In particular, the Company's new
relationship with Microsoft contemplates that the Company will train a
significant number of qualified Microsoft-certified personnel. Competition for
such personnel is intense and there can be no assurances that the Company will
be successful in hiring, motivating or retaining such qualified personnel. The
loss of key personnel or the inability to hire or retain qualified personnel
could have a material adverse effect on the Company's business, financial
condition or results of operations.

      COMPETITION. The information technology ("IT") services industry,
including the network and desktop services markets, is intensely competitive and
undergoing continual change. Worldwide competition is vigorous in all of the
markets in which the Company does business. The Company's competitors are
numerous and vary widely in market position, size and resources. Competitors
differ significantly depending upon the market, customer and geographic area
involved. In many of the Company's markets, traditional computer hardware
manufacturing, communications and consulting companies provide the most
significant competition. The Company must also compete with smaller IT services
businesses providers, but which have, been able to develop strong local or
regional customer bases. Many of the Company's competitors have substantially
greater resources, including larger research and engineering staffs and larger
marketing organizations, than those of the Company. The Company may have
difficulty implementing the leading edge technology required to services its
customers. There can be no assurance that the Company will be able to compete
successfully against other companies that provide similar IT services.


                                       19
<PAGE>   20

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

      YEAR 2000 LIABILITY. The Company supplies computer systems to large
organizations in the commercial and government markets, which include federal,
state and local customers. Any failure of the Company's products to perform,
including system malfunctions due to the onset of the calendar year 2000 (caused
by a data structure problem that will prevent software from properly recognizing
dates after the year 1999), could result in claims against the Company. Although
the Company maintains computer software and services errors and omissions
insurance, a claim brought against the Company could have a material adverse
effect on the Company's business, financial condition or results of operations.
Moreover, an increasing number of the Company's installed base of VS and other
traditional proprietary systems could choose to convert to other calendar year
2000 compliant systems in order to avoid such malfunctions. An increasing rate
of conversion would result in an increasing rate of decline of revenue
associated with such proprietary systems, and could have a material adverse
effect on the Company's business, financial condition or results of operations.
In addition, the Company operates legacy systems and applications that contain
Year 2000 limitations. Initiatives are underway to replace existing systems and
address existing Year 2000 limitations. There can be no assurance that the
conversion will be completed in a timely manner.

      In the course of providing complex, integrated solutions to customers, the
Company frequently forms alliances with third parties that supply both hardware
and software products and services. Future results will in part depend upon the
performance and capabilities of these parties, including their ability to deal
effectively with the Year 2000 issue. The Company is evaluating the impact of
the Year 2000 compliance on its suppliers and is working with its suppliers and
customers on resolving Year 2000 compliance issues. Because the Company relies
on the cooperation and assistance of its suppliers in addressing Year 2000
matters, there remains a possibility that the Company's reliance on its
suppliers could have a material adverse impact on future results.

      POSSIBLE VOLATILITY OF PRICE OF COMMON STOCK. The market price of the
Company's Common Stock has fluctuated significantly in the past and may continue
to fluctuate in the future. Factors such as announcements of technological
innovations or other developments concerning the Company, its competitors or
other third parties, quarterly variations in the Company's results of
operations, non-recurring transactions and changes in overall industry and
economic conditions may all affect the market prices of the Common Stock and
cause it to fluctuate significantly. Moreover, the Company's expense levels are
based in part on expectations of future revenue levels, and a shortfall in
expected revenue could therefore have a disproportionate adverse effect on the
Company's net income. Furthermore, the market prices of the stocks of many high
technology companies have experienced wide fluctuations that have not
necessarily been related to the operating performance of the individual
companies.

      DEPENDENCE ON GOVERNMENT REVENUE. In both the nine months ended March 31,
1998 and the year ended June 30, 1997, the Company derived approximately 30% of
its revenues from branches or agencies of the United States government, and
derived significant additional revenues from agencies of various foreign
governments. The Company expects that a significant portion of the revenue from
the newly-acquired Olsy operations will be attributable to the sale of goods and
services to governments of other countries and their instrumentalities and
agencies. A significant portion of the Company's US government revenues comes
from orders under government contract or subcontract awards, which involves the
risk that the failure to obtain an award, or a delay on the part of the
government agency in making the award or of ordering or paying for products or
services under an awarded contract, could have a material adverse effect on the
financial performance of the Company for the period in question. Other risks
involved in government sales are the larger discounts (and thus lower margins)
often involved in government sales, the unpredictability of funding for various
government programs, and the ability of the government agency to unilaterally
terminate the contract. Revenues from the government of the United States and
other foreign governments and their instrumentalities and agencies, are received
under a number of different contracts and from a number of different contracting
authorities.

      INTERNATIONAL OPERATIONS. International revenues in recent years have
accounted for a substantial portion of the Company's total revenues. As a result
of the acquisition of Olsy, the Company expects to derive more than fifty
percent of its revenue from affiliates operating in non-US environments. The
Company's international operations are subject to all of the risks normally
associated with international sales, including changes in regulatory compliance
requirements, compliance costs associated with International Standards
Organization (ISO) 9000 quality control standards, special standards
requirements, exposure to currency fluctuations, exchange rates, tariffs and
other barriers, difficulties in staffing and managing international subsidiary
operations,


                                       20
<PAGE>   21

                    WANG LABORATORIES, INC. AND SUBSIDIARIES

                MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
                 CONDITION AND RESULTS OF OPERATIONS (CONTINUED)

potentially adverse tax consequences and country-specific product requirements.
The introduction of the Euro may result in changes to business practices
throughout Europe affecting pricing, systems and competition. While the Company
attempts to reduce its currency exposure, there can be no assurance that it will
not experience losses due to international currency fluctuations. The Company's
results of operations could also be affected by economic conditions and changes
in foreign countries and by macro-economic changes, including recession and
inflation. For example, weakness in some Asian markets may have an adverse
impact on the Company's business. In addition, effective intellectual property
protection may not be available in every foreign country in which the Company
distributes its own and other products and the loss of such protection could
have a material adverse effect on the business of the Company.

      NATURE OF CONTRACTS. Some of the Company's contracts are for a fixed price
and are long-term in duration, which subjects the Company to substantial risks
relating to unexpected cost increases and other factors outside the control of
the Company. Revenues and profits on such contracts are recognized using
estimates and actual results, when known, may differ materially from such
estimates. Additionally, some of the customer relationships in the international
arena, particularly those acquired through the Olsy acquisition, are supported
by purchase orders in lieu of contracts of a predetermined duration. Revenues
supported by purchase orders are often less predictable and may be jeopardized
by the acquisition of Olsy by the Company. Finally, IT outsourcing contracts in
particular, often contain provisions that allow for termination for convenience,
service level agreement compliance, liquidated damages and penalties and are
awarded based on a competitive procurement process. Such contracts often require
high expenditures and long lead times with no assurance of success.

      SUPERIOR RIGHTS OF PREFERRED STOCK. The Board of Directors of the Company
is authorized under the Company's Certificate of Incorporation, without
stockholder approval, to issue from time to time up to an aggregate of 5,000,000
shares of preferred stock, $0.01 par value per share (the "Preferred Stock"), in
one or more series. Of the 5,000,000 authorized shares of Preferred Stock,
90,000 shares have been designated as 4 1/2% Series A Cumulative Convertible
Preferred Stock (the "Series A Preferred Stock"), all of which shares have been
issued, and 143,750 shares have been designated as 6 1/2% Series B Cumulative
Convertible Preferred Stock ("Series B Preferred Stock"), all of which shares
have been issued. The rights of holders of Common Stock are subject to, and may
be adversely affected by, the rights of holders of the Series A Preferred Stock
and the Series B Preferred Stock and any other series of Preferred Stock that
the Company may designate and issue in the future. In particular, before any
payment or distribution is made to holders of Common Stock upon the liquidation,
dissolution or winding-up of the Company, holders of both the Series A Preferred
Stock and the Series B Preferred Stock are entitled to receive a liquidation
preference of $1,000.00 per share, plus accrued and unpaid dividends. The
holders of the Series A Preferred Stock and the Series B Preferred Stock also
have various rights, preferences and privileges with respect to dividends,
redemption, voting, conversion and registration under the Securities Act.

      AVAILABILITY OF FINANCING. The Company may need to raise additional funds
through public or private debt or equity offerings in order to make other
acquisitions and otherwise implement its strategy. The Company has recently
entered into a $500 million secured credit facility in conjunction with the
completion of the transaction with Olivetti. While the Company believes that the
facility provides sufficient capital availability there can be no assurance that
sufficient capital will be available on terms acceptable to the Company.

      ANTI-TAKEOVER PROVISIONS. The Company's Certificate of Incorporation and
By-Laws1 and the Delaware General Corporation Law contain certain provisions
which could have the effect of delaying or preventing transactions that might
result in a change in control of the Company, including transactions in which
stockholders might otherwise receive a premium for their shares over the
then-current market price, and may limit the ability of stockholders to approve
transactions that they deem to be in their best interests. In addition, the
Company has recently adopted a shareholder rights plan which is intended to
deter coercive or unfair takeover tactics and to prevent a potential acquirer
from gaining control of the Company without offering a fair price to all of the
Company's shareholders.


                                       21
<PAGE>   22

                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

DATE: April 5, 1999

                                               WANG LABORATORIES, INC.


                                               /s/ Paul A. Brauneis
                                               --------------------------------
                                               Paul A. Brauneis,
                                               Vice President and
                                               Corporate Controller


                                       22

<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM (A) THE
CONSOLIDATED BALANCE SHEETS, CONSOLIDATED STATEMENT OF OPERATIONS AND
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH (B) FORM 10-Q/A
AMENDMENT NO. 1 TO FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1998.
</LEGEND>
<RESTATED> 
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          JUN-30-1998
<PERIOD-START>                             JUL-01-1997
<PERIOD-END>                               MAR-31-1998
<EXCHANGE-RATE>                                      1
<CASH>                                         238,700
<SECURITIES>                                         0
<RECEIVABLES>                                  810,600
<ALLOWANCES>                                    19,800
<INVENTORY>                                    188,700
<CURRENT-ASSETS>                             1,419,100
<PP&E>                                         453,800<F1>
<DEPRECIATION>                                 161,700<F1>
<TOTAL-ASSETS>                               2,279,600
<CURRENT-LIABILITIES>                        1,272,200
<BONDS>                                        120,300
                           86,000
                                    138,300
<COMMON>                                           500
<OTHER-SE>                                     484,600
<TOTAL-LIABILITY-AND-EQUITY>                 2,279,600
<SALES>                                        272,200
<TOTAL-REVENUES>                             1,053,700
<CGS>                                          211,700
<TOTAL-COSTS>                                  825,200
<OTHER-EXPENSES>                                48,000<F2>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               6,700
<INCOME-PRETAX>                                (7,700)
<INCOME-TAX>                                    13,400
<INCOME-CONTINUING>                           (21,100)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (21,100)
<EPS-PRIMARY>                                   (0.82)
<EPS-DILUTED>                                   (0.82)
<FN>
<F1>PP&G COST AND ACCUMULATED DEPRECIATION INCLUDE CAPITALIZED NONCONSUMABLE 
SPACES INVENTORY.
<F2>OTHER COSTS AND EXPENSES INCLUDES $23.2 MILLION OF NET ACQUISITION-RELATED,
RESTRUCTURING AND CHAPTER 11-RELATED CHARGES.
</FN>
        

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission